Synonym |
Thai / English name |
Part Used : ดอกActivity : CYP2D4 INHIBITIONSolvent/Active Compound : Hydroxysafflor yellow A (HSYA)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 3.0 mg/kgDuration : 3 daysType of interaction : PharmacokineticsInteraction with drug : Dextromethorphan*/Dextromethorfan/DextromorphanDose/Conc.(drug) : -Result : EquivocalRemark : Drug; On the fourth day, a cocktail solution at a dose of 5 mL/kg, which contained phenacetin (20 mg/kg), tolbutamide (5 mg/kg), dextromethorphan (20 mg/kg) and midazolam (10 mg/kg) in CMC-Na solution, was administered orally to all rats in each group. Blood samples of each rat were collected pre-dose (0 h) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 h after probe drugs administration through the tail vein. Results; The pharmacokinetic parameters of dextromethorphan in rats showed no significant difference between different treatment groups and BCG.Note : T1/2: half-life; Tmax: the time of peak concentration; Cmax: the peak or maximum concentration; AUC(0-infinity): area under a curve extrapolated to infinity; MRT: mean residence time; CL: the total body clearance; BCG: blank control group; LSG: low dosage (3.0 mg/kg/day) and short period (3 days) group; LLG: low dosage and long period (14 days) group; HSG: high dosage (12.0 mg/kg/day) and short period group; HLG: high dosage and long period group.
Part Used : ดอกActivity : CYP2D4 INHIBITIONSolvent/Active Compound : Hydroxysafflor yellow A (HSYA)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 12.0 mg/kgDuration : 3 daysType of interaction : PharmacokineticsInteraction with drug : Dextromethorphan*/Dextromethorfan/DextromorphanDose/Conc.(drug) : -Result : EquivocalRemark : Drug; On the fourth day, a cocktail solution at a dose of 5 mL/kg, which contained phenacetin (20 mg/kg), tolbutamide (5 mg/kg), dextromethorphan (20 mg/kg) and midazolam (10 mg/kg) in CMC-Na solution, was administered orally to all rats in each group. Blood samples of each rat were collected pre-dose (0 h) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 h after probe drugs administration through the tail vein. Results; The pharmacokinetic parameters of dextromethorphan in rats showed no significant difference between different treatment groups and BCG.Note : T1/2: half-life; Tmax: the time of peak concentration; Cmax: the peak or maximum concentration; AUC(0-infinity): area under a curve extrapolated to infinity; MRT: mean residence time; CL: the total body clearance; BCG: blank control group; LSG: low dosage (3.0 mg/kg/day) and short period (3 days) group; LLG: low dosage and long period (14 days) group; HSG: high dosage (12.0 mg/kg/day) and short period group; HLG: high dosage and long period group.
Part Used : ดอกActivity : CYP2D4 INHIBITIONSolvent/Active Compound : Hydroxysafflor yellow A (HSYA)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 3.0 mg/kgDuration : 14 daysType of interaction : PharmacokineticsInteraction with drug : Dextromethorphan*/Dextromethorfan/DextromorphanDose/Conc.(drug) : -Result : EquivocalRemark : Drug; On the eleventh or fifteenth day, a cocktail solution at a dose of 5 mL/kg, which contained phenacetin (20 mg/kg), tolbutamide (5 mg/kg), dextromethorphan (20 mg/kg) and midazolam (10 mg/kg) in CMC-Na solution, was administered orally to all rats in each group. Blood samples of each rat were collected pre-dose (0 h) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 h after probe drugs administration through the tail vein. Results; The pharmacokinetic parameters of dextromethorphan in rats showed no significant difference between different treatment groups and BCG.Note : T1/2: half-life; Tmax: the time of peak concentration; Cmax: the peak or maximum concentration; AUC(0-infinity): area under a curve extrapolated to infinity; MRT: mean residence time; CL: the total body clearance; BCG: blank control group; LSG: low dosage (3.0 mg/kg/day) and short period (3 days) group; LLG: low dosage and long period (14 days) group; HSG: high dosage (12.0 mg/kg/day) and short period group; HLG: high dosage and long period group.
Part Used : ดอกActivity : CYP2D4 INHIBITIONSolvent/Active Compound : Hydroxysafflor yellow A (HSYA)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 12.0 mg/kgDuration : 14 daysType of interaction : PharmacokineticsInteraction with drug : Dextromethorphan*/Dextromethorfan/DextromorphanDose/Conc.(drug) : -Result : EquivocalRemark : Drug; On the eleventh or fifteenth day, a cocktail solution at a dose of 5 mL/kg, which contained phenacetin (20 mg/kg), tolbutamide (5 mg/kg), dextromethorphan (20 mg/kg) and midazolam (10 mg/kg) in CMC-Na solution, was administered orally to all rats in each group. Blood samples of each rat were collected pre-dose (0 h) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 h after probe drugs administration through the tail vein. Results; The pharmacokinetic parameters of dextromethorphan in rats showed no significant difference between different treatment groups and BCG.Note : T1/2: half-life; Tmax: the time of peak concentration; Cmax: the peak or maximum concentration; AUC(0-infinity): area under a curve extrapolated to infinity; MRT: mean residence time; CL: the total body clearance; BCG: blank control group; LSG: low dosage (3.0 mg/kg/day) and short period (3 days) group; LLG: low dosage and long period (14 days) group; HSG: high dosage (12.0 mg/kg/day) and short period group; HLG: high dosage and long period group.
Part Used : ดอกActivity : CYP2D4 INHIBITIONSolvent/Active Compound : Hydroxysafflor yellow A (HSYA)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 3.0 mg/kg/dayDuration : 3 daysType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : NegativeRemark : Results; no differences in the mRNA expression level of CYP2D4 was observed between HSYA different treatment groups and BCG.Note : T1/2: half-life; Tmax: the time of peak concentration; Cmax: the peak or maximum concentration; AUC(0-infinity): area under a curve extrapolated to infinity; MRT: mean residence time; CL: the total body clearance; BCG: blank control group; LSG: low dosage (3.0 mg/kg/day) and short period (3 days) group; LLG: low dosage and long period (14 days) group; HSG: high dosage (12.0 mg/kg/day) and short period group; HLG: high dosage and long period group.
Part Used : ดอกActivity : CYP2D4 INHIBITIONSolvent/Active Compound : Hydroxysafflor yellow A (HSYA)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 12.0 mg/kg/dayDuration : 3 daysType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : NegativeRemark : Results; no differences in the mRNA expression level of CYP2D4 was observed between HSYA different treatment groups and BCG.Note : T1/2: half-life; Tmax: the time of peak concentration; Cmax: the peak or maximum concentration; AUC(0-infinity): area under a curve extrapolated to infinity; MRT: mean residence time; CL: the total body clearance; BCG: blank control group; LSG: low dosage (3.0 mg/kg/day) and short period (3 days) group; LLG: low dosage and long period (14 days) group; HSG: high dosage (12.0 mg/kg/day) and short period group; HLG: high dosage and long period group.
Part Used : ดอกActivity : CYP2D4 INHIBITIONSolvent/Active Compound : Hydroxysafflor yellow A (HSYA)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 3.0 mg/kg/dayDuration : 14 daysType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : NegativeRemark : Results; no differences in the mRNA expression level of CYP2D4 was observed between HSYA different treatment groups and BCG.Note : T1/2: half-life; Tmax: the time of peak concentration; Cmax: the peak or maximum concentration; AUC(0-infinity): area under a curve extrapolated to infinity; MRT: mean residence time; CL: the total body clearance; BCG: blank control group; LSG: low dosage (3.0 mg/kg/day) and short period (3 days) group; LLG: low dosage and long period (14 days) group; HSG: high dosage (12.0 mg/kg/day) and short period group; HLG: high dosage and long period group.
Part Used : ดอกActivity : CYP2D4 INHIBITIONSolvent/Active Compound : Hydroxysafflor yellow A (HSYA)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 12.0 mg/kg/dayDuration : 14 daysType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : NegativeRemark : Results; no differences in the mRNA expression level of CYP2D4 was observed between HSYA different treatment groups and BCG.Note : T1/2: half-life; Tmax: the time of peak concentration; Cmax: the peak or maximum concentration; AUC(0-infinity): area under a curve extrapolated to infinity; MRT: mean residence time; CL: the total body clearance; BCG: blank control group; LSG: low dosage (3.0 mg/kg/day) and short period (3 days) group; LLG: low dosage and long period (14 days) group; HSG: high dosage (12.0 mg/kg/day) and short period group; HLG: high dosage and long period group.